Akkermansia muciniphila, a key player in the gut microbiome, has emerged as a significant influencer of GLP-1, a hormone with profound implications for metabolic health.

Learn from Adam Perlman, MD, MPH, Chief Medical Officer of Pendulum Therapeutics, about the latest research uncovering the impact of A. muciniphila, C.butyricum, B.infantis and other novel microbial strains on GLP-1 signaling, satiety, cravings, and the potential of probiotics for metabolic disorders.

Learning objectives: 

1. Understand the role of GLP-1 (Glucagon-Like Peptide-1) in gut metabolism and its significance in metabolic health
2. Identify the mechanisms by which targeted probiotics can influence GLP-1 secretion and metabolism
3. Detail the science and evidence for the use of a synbiotic specifically formulated to improve gut health and food cravings

Adam Perlman, MD, MPH is the Chief Medical Officer at Pendulum Therapeutics. He formerly served as the Director of Integrative Health and Wellbeing at Mayo Clinic, Florida, and Medical Director for Employee Wellbeing. Prior to that, he was Associate Vice President for Health and Wellness for the Duke University Health System, overseeing Duke Integrative Medicine and the Duke Diet Center. Dr. Perlman received his BA from Tufts University and his MD from Boston University School of Medicine, completing residencies in Internal Medicine and Preventive Medicine as well as a General Internal Medicine Research Fellowship at Boston Medical Center. He earned an MPH from the Boston University School of Public Health.

Sponsored by: PENDULUM HEALTH